Tech Company Inital Public Offerings
Delcath Systems IPO
Delcath Systems was acquired by . The company's stock became public on 3/28/2023.
Transaction Overview
Company Name
Announced On
3/28/2023
Transaction Type
IPO
Amount
$85,000,000
Proceeds Purpose
This financing is expected to enable the company to have sufficient cash past its anticipated PDUFA date of August 14, 2023, and fund the commercialization of HEPZATO, if approved.
Company Information
Company Status
Private & Independent
Industry
Healthcare Services
Mailing Address
1633 Broadway 22nd Fl C
New York,, NY 10019
USA
New York,, NY 10019
USA
Phone
Undisclosed
Website
Email Address
Overview
Delcath Systems, Inc. is an interventional oncology company focused on the treatment of primary and metastatic liver cancers. At Delcath, we look beyond the ordinary and strive for excellence in all that we do. Our investigational product, HEPZATO� KIT (melphalan hydrochloride for injection/hepatic delivery system), is designed to administer high-dose chemotherapy to the liver, while controlling systemic exposure and associated side effects.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Gerard Michel
Chief Operating Officer
John Purpura
Vice President
Johnny John
Vice President
Kevin Muir
Browse more venture capital transactions:
Prev: 3/28/2023: 3E Nano venture capital transaction
Next: 3/28/2023: Relu venture capital transaction
Share this article
News on VC Transactions
We do our best to report on every notable VC transaction. VC transactions on this site are sourced from news reports and company announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs